Engineered Protein Oxygen Carriers: a novel blood substitute for trauma care
工程蛋白载氧体:一种用于创伤护理的新型血液替代品
基本信息
- 批准号:9899822
- 负责人:
- 金额:$ 20.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-04-01 至 2023-03-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAfghanistanAmbulancesAmericanAmino Acid SubstitutionAmino AcidsAnaerobic BacteriaAnaphylaxisAnimalsAntibodiesBehavioralBindingBinding SitesBiological AssayBiological MarkersBiomedical EngineeringBiophysicsBloodBlood CirculationBlood Gas AnalysisBlood Pressure MonitorsBlood SubstitutesBlood TransfusionBlood gasBody TemperatureCaringCarrier ProteinsCellsCessation of lifeChargeChemicalsClinicalConflict (Psychology)CoupledCrystallizationCustomDataDiseaseDrug KineticsEmergency CareEmergency SituationEngineeringEnsureEnvironmentEnzyme-Linked Immunosorbent AssayErythrocytesEscherichia coliFailureFlow CytometryFunctional disorderGasesGift GivingGoalsHalf-LifeHarvestHealthHeartHemeHemeproteinsHemoglobinHemorrhageHemorrhagic ShockHistologyHourHypertensionIV FluidInnovative TherapyIraqKidneyKineticsLacerationLactated Ringer&aposs SolutionLeadLibrariesLifeLigandsLinkLiverLungMass Spectrum AnalysisMeasuresMedicalMetabolic Clearance RateMetabolismMilitary PersonnelMitochondriaModelingModernizationMolecular WeightMyoglobinNitric OxideOrganOutcomeOxygenPatientsPerformancePharmacologyPhysiologicalPopulationPowder dose formPropertyProtein EngineeringProteinsRattusRefrigerationResolutionResuscitationRiskRodentRodent ModelRuralSafetySeriesSerumShockSiteStructureTestingTimeTissuesToxic effectTransfusionTranslatingTraumatic HemorrhageVariantVascular blood supplyalpha helixbaseblood productdensitydesigneffective therapyhistological stainsimmune activationimmunogenicimmunogenicityimmunoreactionimprovednovelorgan injurypathogenphysical propertypreclinical efficacypreclinical safetypressurepreventprotein transportscreeningskillssuccesstime usetissue oxygenationtransfusion medicinetrauma carevasoconstriction
项目摘要
There is a pressing need for artificial oxygen (O2) carriers as an alternative to donated blood/blood
products. For victims of life-threatening hemorrhage, transfusion is the most effective treatment, yet
nearly 25% of the nation's blood centers are perennially in short supply. Additionally, the perishability of
blood products coupled with blood's potential for immunologic reactions, makes the transfusion of blood
products highly problematic in non-hospital settings. The issue of timely access to blood is particularly
challenging in austere environments (i.e. battle field, rural site) where lengthy transports to definitive
care may be required. Unfortunately, failure to transfuse blood within the “golden hour” increases the
risk of poor clinical outcomes including death.
The proposed studies aim to use modern advances in de novo designed artificial heme proteins
to over come the design limitations of earlier emergency blood substitutes based on natural hemoglobin..
Engineered Protein O2 Carriers (EPOCs) are inherently more adaptable than hemoglobins, allowing
direct control of gaseous ligand affinity. EPOCs also offer control over thermal stability (autoclavability),
molecular weight and net charge (blood clearance rates), density of O2 binding sites per protein
(transport capacity) as well as other desirable physical properties. Importantly, our preliminary results in
a rodent hemorrhagic shock model suggest that EPOCs enhance tissue oxygen deliver compared to
standard lactated Ringers resuscitation.
This proposal will use diverse amino acid substitutions at three specific sites in contact with the
O2 binding hemes in the EPOC frame to generate a large library of EPOC variants. These variants will
be rapidly screened to select three EPOCs with high, medium, and low O2 affinity, while maintaining tight
heme binding. They will also be selected for low nitric oxide binding to avoid potential counterproductive
vascular constriction. An initial screening trial in rats using EPOCs to replace blood lost to hemorrhage
will identify if any of the three classes of O2 affinities performs better than our current EPOC in circulation.
The leading EPOC candidate will then be tested in larger rat trials for pharmacological safety, blood
stability and clearance, and potential immunogenicity or toxicity. Another series of rodent trials will
quantitate EPOC efficiency at treating severe hemorrhagic shock, in both a shock model with controlled
bleeding and a freely hemorrhaging liver laceration shock model.
By establishing the best properties for EPOCs in circulation and establishing their safety and
efficacy, we will provide the means necessary to build a safe, effective and durable O2 carrier with the
ultimate goal of expanding the nation's access to emergency “blood” products and revolutionizing
transfusion medicine.
迫切需要人造氧(O2)载体作为捐献血液/血液的替代品
产品.对于危及生命的出血患者,输血是最有效的治疗方法,但
全国近25%的血液中心常年供应不足。此外,
血液制品加上血液的潜在免疫反应,使得输血
产品在非医院环境中存在很大问题。及时获得血液的问题尤其重要,
在严峻的环境中(即战场,农村地区)具有挑战性,
可能需要小心。不幸的是,未能在“黄金时间”内输血,
不良临床结局的风险,包括死亡。
拟议的研究旨在利用现代先进的从头设计的人工血红素蛋白
克服早期基于天然血红蛋白的紧急血液替代品的设计局限性。
工程蛋白O2载体(EPOC)本质上比血红蛋白更具适应性,
直接控制气体配体亲和力。EPOC还提供对热稳定性(高压灭菌性)的控制,
分子量和净电荷(血液清除率),每个蛋白质的O2结合位点密度
(输送能力)以及其它所需的物理性质。重要的是,我们的初步结果
啮齿类动物失血性休克模型表明,与对照组相比,
标准乳酸林格氏复苏。
该提议将在与蛋白质结合的三个特定位点处使用不同的氨基酸取代。
O2结合血红素的EPOC框架,以产生一个大的EPOC变体库。这些变体将
快速筛选,以选择具有高,中,低O2亲和力的三种EPOC,同时保持紧密的
血红素结合他们也将被选择为低一氧化氮结合,以避免潜在的适得其反
血管收缩在大鼠中使用EPOC替代失血的初步筛选试验
将确定三种O2亲和力中的任何一种是否比我们目前流通中的EPOC表现更好。
然后,将在更大的大鼠试验中测试领先的EPOC候选药物的药理学安全性,血液
稳定性和清除率以及潜在的免疫原性或毒性。另一系列啮齿动物试验将
定量EPOC治疗严重失血性休克的效率,在休克模型和对照模型中,
出血和自由落体式肝裂伤休克模型。
通过确定EPOC在流通中的最佳特性,并确定其安全性,
有效性,我们将提供必要的手段,建立一个安全,有效和持久的O2载体,
最终目标是扩大国家获得紧急“血液”产品的机会,
输血医学
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bohdana Discher其他文献
Bohdana Discher的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Drought and Climate Resilience of Smallholders in Afghanistan: Needs and Preferences Analysis
阿富汗小农的干旱和气候抵御能力:需求和偏好分析
- 批准号:
24K16366 - 财政年份:2024
- 资助金额:
$ 20.25万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
'Diaspora States' in Somalia and Afghanistan: New Perspectives on Post-War Politics, Dual Citizenship and International Statebuilding
索马里和阿富汗的“侨民国家”:战后政治、双重国籍和国际国家建设的新视角
- 批准号:
EP/X022048/1 - 财政年份:2023
- 资助金额:
$ 20.25万 - 项目类别:
Fellowship
Improving learning outcomes in Afghanistan and Pakistan in the midst of COVID-19 through Community based system dynamics and project-based learning
通过基于社区的系统动态和基于项目的学习,在 COVID-19 期间改善阿富汗和巴基斯坦的学习成果
- 批准号:
ES/X014088/1 - 财政年份:2022
- 资助金额:
$ 20.25万 - 项目类别:
Research Grant
On Politics and Justice: British Military Justice following War Crimes Allegations in Iraq and Afghanistan, 2001-present
论政治与司法:2001 年至今,伊拉克和阿富汗战争罪指控后的英国军事司法
- 批准号:
2745904 - 财政年份:2022
- 资助金额:
$ 20.25万 - 项目类别:
Studentship
U.S and Afghanistan - why the nation-building project failed?
美国和阿富汗——国家建设项目为何失败?
- 批准号:
22K01385 - 财政年份:2022
- 资助金额:
$ 20.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Market Economy and Conflict; Disjuncture between the Politics and Economics of Statebuilding in Afghanistan during 2001-2021
市场经济与冲突;
- 批准号:
ES/X006832/1 - 财政年份:2022
- 资助金额:
$ 20.25万 - 项目类别:
Fellowship
Analysis of the structure of conflict between ethnicities in the transformation of national integration policy in Afghanistan
阿富汗民族融合政策转型中的族群冲突结构分析
- 批准号:
19K20529 - 财政年份:2019
- 资助金额:
$ 20.25万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Neurosteroid Intervention for PTSD in Iraq/Afghanistan-era Veterans
神经类固醇干预伊拉克/阿富汗时期退伍军人的创伤后应激障碍
- 批准号:
10417141 - 财政年份:2019
- 资助金额:
$ 20.25万 - 项目类别:
Neurosteroid Intervention for PTSD in Iraq/Afghanistan-era Veterans
神经类固醇干预伊拉克/阿富汗时期退伍军人的创伤后应激障碍
- 批准号:
10589071 - 财政年份:2019
- 资助金额:
$ 20.25万 - 项目类别:
A pilot assessment of miltefosine's efficacy and tolerability for treating cutaneous Leishmania tropica in Afghanistan
在阿富汗对米替福辛治疗皮肤热带利什曼原虫的疗效和耐受性进行初步评估
- 批准号:
MR/R018391/1 - 财政年份:2018
- 资助金额:
$ 20.25万 - 项目类别:
Research Grant